What is Alpelisib-Piqray?

Alpelisib (Alpelisib)-Piqray is an oral small molecule inhibitor of phosphoinositide-3 kinase (PIK3CA) α catalytic subunit. PIK3CA is an important mediator of cell growth and proliferation. PIK3CA mutations are found in many forms of cancer, including breast, ovarian and colorectal cancer. These mutations lead to dysregulation of cell growth, differentiation, proliferation, and apoptosis, pathways that are important in the development of cancer.

Specific mutations in PIK3CA are most common (approximately 40%) in hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) breast cancers. In postmenopausal women with cancer, clinical trials of apelvis combined with an anti-estrogen (Fulvestrant) demonstrated prolonged overall survival and progression-free survival. Increased overall response rates were found only in patients with cancermutated PIK3CA, but not in patients with unmutated wild-type PIK3CA. Apellis is available in tablets of 50, 150 and 200 mg, and is marketed under the brand name Piqray.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.